We aspire to be a partner of choice by offering sophisticated and integrated capabilities in research, development, and manufacturing, combined with powerful data and digital insights to expand patient access to the latest medicines.
The core of our business model is to work with and support our asset partners, helping to fully realize the potential of their innovations and optimize their return on investment. Focusing 100% on Chinese patients, healthcare systems, and access, we are building best-in-class R&D and commercial platforms that ensure compliance, quality, and appropriate use of our medicines.
We welcome partners around the globe who share our vision. Our priority is to invest in clinical stage assets with demonstrated efficacy, or portfolios where multiple product opportunities and synergies exist. We are also interested in cutting-edge platforms where multiple products can be rapidly discovered and developed.
Brii Bio has established a partnership with VBI Vaccines (www.vbivaccines.com)
Brii Bio has entered into a license and collaboration agreement with VBI Vaccines (www.vbivaccines.com) for greater China rights to VBI-2601, a recombinant protein-based immunotherapeutic with the potential to contribute to a functional cure for HBV. VBI Vaccines is a commercial-stage biopharmaceutical company developing the next generation of vaccines to address unmet needs in infectious diseases and immune-oncology (NASDAQ:VBIV).
Brii Bio has established a partnership with Vir Biotechnology (www.vir.bio)
Brii Bio has established a partnership with Vir Biotechnology (www.vir.bio), a leading U.S.-based biotech working to find cures for infectious diseases, that grants Brii Bio options on exclusive greater China rights for up to four assets in Vir’s infectious diseases portfolio. This therapeutic pipeline holds the potential to prevent, treat, and cure a wide range of infectious diseases.
Brii Bio and Vir Biotechnology have agreed to commence clinical development efforts in China for VIR-2218, a novel, investigational RNA interference (RNAi) therapeutic designed to inhibit expression of all HBV proteins, including hepatitis B surface antigen (HBsAg). Viral protein knockdown may help restore the patient’s own immune response to HBV, thereby offering people living with chronic HBV the potential for a functional cure. This is the first asset that Brii Bio will take into the clinic as part of its existing partnership with Vir in infectious disease, under which Brii Bio will develop and commercialize up to four assets from Vir’s pipeline.
Brii Bio has established an exclusive research partnership with Tsinghua University Institute for Immunology
Brii Bio has entered into exclusive research collaboration with Tsinghua University Institute for Immunology, a world-class academic research institute in Beijing, to discover and develop bispecific antibodies to treat infectious diseases and other immunologic disorders. Brii Bio and Tsinghua University will collaborate on China-based innovation for novel immunotherapeutics building on Tsinghua’s world class expertise in immunology. Tsinghua investigators will provide laboratory facilities, bespoke assays and deep immunology expertise. Brii Bio will sponsor a joint post-doctoral fellowship with Tsinghua University and provide discovery insight for novel immune therapies. Brii Bio will retain global rights of all products arising from these collaborations.
Brii Bio has established an exclusive research partnership with WuXi Biologics (www.wuxibiologics.com)
Brii Bio has entered into exclusive research collaboration with WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company, to discover and develop bispecific antibodies to treat infectious diseases and other immunologic disorders. This collaboration will give Brii Bio access to WuXi Biologics’ end-to-end biopharmaceutical technology platforms and capabilities, and will enable discovery, development, and manufacture of biologic products in China. Brii Bio will retain global rights of all products arising from these collaborations.
Brii Bio has established a partnership with Tsinghua Industrial R&D Institute
Brii Bio has established a multi-year partnership with Tsinghua Industrial R&D Institute, accelerating development and commercialization of innovative therapeutics. Brii Bio will co-fund and advise discovery incubators with Tsinghua Industrial R&D Institute.
Brii Bio has signed a memorandum of understanding to create a first-of-its-kind partnership with Alihealth (www.alihealth.cn).
Brii Bio has signed a memorandum of understanding to create a first-of-its-kind partnership with Alihealth (www.alihealth.cn). We believe Alihealth’s digital and data capabilities and access to healthcare information will help us optimize clinical development, generate value-based evidence, and enable better market access for innovative medicines through patient education and physician support.
Brii Bio has established a long-term partnership with WuXi AppTec (www.wuxiapptec.com) and WuXi Biologics (www.wuxibiologics.com)
Brii Bio has established a long-term partnership with WuXi AppTec (www.wuxiapptec.com) and WuXi Biologics (www.wuxibiologics.com), or collectively WuXi, to gain priority access to its best-in-class end-to-end R&D capabilities. This will allow us to focus on building core competencies in key therapeutic areas and specific products. We will create a “one team” way of working with WuXi through our shared vision and commitment.